Empirical Finance LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,416 shares of the biotechnology company’s stock after acquiring an additional 14 shares during the period. United Therapeutics Corporation accounts for about 0.7% of Empirical Finance LLC’s holdings, making the stock its 28th biggest position. Empirical Finance LLC’s holdings in United Therapeutics Corporation were worth $1,871,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Focused Wealth Management Inc increased its position in United Therapeutics Corporation by 17.5% during the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 140 shares during the period. Daiwa Securities Group Inc. increased its position in United Therapeutics Corporation by 17.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after purchasing an additional 200 shares during the period. Campbell & CO Investment Adviser LLC acquired a new position in United Therapeutics Corporation during the 1st quarter worth approximately $204,000. Eagle Global Advisors LLC acquired a new position in United Therapeutics Corporation during the 2nd quarter worth approximately $206,000. Finally, Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation during the 1st quarter worth approximately $230,000.
United Therapeutics Corporation (NASDAQ UTHR) traded up 0.76% during midday trading on Tuesday, reaching $121.67. The company had a trading volume of 117,550 shares. The company’s 50 day moving average is $130.11 and its 200-day moving average is $130.35. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a market capitalization of $5.29 billion, a P/E ratio of 14.11 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The business had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.42 earnings per share. Equities analysts expect that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Empirical Finance LLC Buys 14 Shares of United Therapeutics Corporation (UTHR)” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2017/09/12/empirical-finance-llc-buys-14-shares-of-united-therapeutics-corporation-uthr.html.
Several research firms have issued reports on UTHR. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research report on Friday. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. ValuEngine cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, UBS AG reiterated a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $134.50.
In related news, CEO Martine A. Rothblatt sold 1,238 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $130.20, for a total value of $161,187.60. Following the completion of the transaction, the chief executive officer now owns 1,378 shares of the company’s stock, valued at approximately $179,415.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Dwek sold 3,490 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Insiders have sold 25,178 shares of company stock valued at $3,289,427 over the last 90 days. 7.80% of the stock is currently owned by insiders.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.